Immunitybio Inc
IBRX2.375USD
+0.005+0.21%
交易中 （美東）報價延遲15分鐘
2.03B總市值
虧損本益比TTM
關於 Immunitybio Inc 公司
Immunitybio, Inc. 是一家垂直整合的臨牀階段生物技術公司，致力於開發能夠增強自然免疫系統以對抗癌症和傳染病的療法和疫苗。該公司利用其專有平臺來增強免疫系統的先天性和適應性分支，開發先進的療法和疫苗以對抗泌尿系統癌症和其他癌症以及傳染病。其平臺及其相關候選產品旨在通過以協調的方式激活先天免疫系統（包括 NK 細胞、樹突狀細胞和巨噬細胞）以及適應性免疫系統（包括 B 細胞和 T 細胞）來攻擊癌症和傳染性病原體。其生物候選產品開發平臺包括抗體-細胞因子融合蛋白、DNA、RNA 和重組蛋白疫苗以及細胞療法。其領先的生物商業候選產品 Anktiva 是一種 IL-15 超激動劑抗體-細胞因子融合蛋白。
公司簡介
公司代碼IBRX
公司名稱Immunitybio Inc
上市日期Jul 28, 2015
CEOMr. Richard Adcock
員工數量680
證券類型Ordinary Share
年結日Jul 28
公司地址3530 John Hopkins Court
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92121
電話18446965235
網址https://immunitybio.com/
公司代碼IBRX
上市日期Jul 28, 2015
CEOMr. Richard Adcock
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Patrick Soon-Shiong, M.D.
Dr. Patrick Soon-Shiong, M.D.
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
35.16M
--
Mr. Richard Adcock
Mr. Richard Adcock
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
334.42K
--
Mr. Michael D. Blaszyk
Mr. Michael D. Blaszyk
Independent Director
Independent Director
265.58K
--
Ms. Cheryl L. Cohen
Ms. Cheryl L. Cohen
Lead Independent Director
Lead Independent Director
200.62K
--
Dr. Linda Maxwell, M.D.
Dr. Linda Maxwell, M.D.
Independent Director
Independent Director
--
--
Mr. David Sachs
Mr. David Sachs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Barry J. Simon, M.D.
Dr. Barry J. Simon, M.D.
Chief Corporate Affairs, Director
Chief Corporate Affairs, Director
--
--
Ms. Christobel E. Selecky
Ms. Christobel E. Selecky
Independent Director
Independent Director
--
--
Gen. (Retd.) Wesley Clark
Gen. (Retd.) Wesley Clark
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Patrick Soon-Shiong, M.D.
Dr. Patrick Soon-Shiong, M.D.
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
35.16M
--
Mr. Richard Adcock
Mr. Richard Adcock
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
334.42K
--
Mr. Michael D. Blaszyk
Mr. Michael D. Blaszyk
Independent Director
Independent Director
265.58K
--
Ms. Cheryl L. Cohen
Ms. Cheryl L. Cohen
Lead Independent Director
Lead Independent Director
200.62K
--
Dr. Linda Maxwell, M.D.
Dr. Linda Maxwell, M.D.
Independent Director
Independent Director
--
--
Mr. David Sachs
Mr. David Sachs
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2024
FY2023
FY2022
FY2021
暫無數據
地區USD
名稱
營收
佔比
United States
14.21M
96.40%
Europe
531.00K
3.60%
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Cambridge Equities, L.P.
69.59%
Soon-Shiong (Patrick)
3.98%
The Vanguard Group, Inc.
2.30%
BlackRock Institutional Trust Company, N.A.
1.31%
State Street Global Advisors (US)
0.86%
Other
21.95%
持股股東
持股股東
佔比
Cambridge Equities, L.P.
69.59%
Soon-Shiong (Patrick)
3.98%
The Vanguard Group, Inc.
2.30%
BlackRock Institutional Trust Company, N.A.
1.31%
State Street Global Advisors (US)
0.86%
Other
21.95%
股東類型
持股股東
佔比
Corporation
69.59%
Investment Advisor
5.18%
Individual Investor
4.48%
Investment Advisor/Hedge Fund
2.27%
Hedge Fund
0.88%
Research Firm
0.88%
Bank and Trust
0.08%
Pension Fund
0.05%
Venture Capital
0.01%
Other
16.58%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
422
736.69M
83.41%
+107.95M
2025Q1
440
618.65M
87.38%
-10.66M
2024Q4
423
621.25M
74.01%
+7.18M
2024Q3
400
607.11M
84.02%
-2.53M
2024Q2
394
600.23M
83.10%
-13.23M
2024Q1
370
604.61M
90.46%
-1.82M
2023Q4
363
595.85M
89.24%
+717.13K
2023Q3
366
588.92M
88.35%
+213.08M
2023Q2
362
368.64M
84.54%
-18.27M
2023Q1
371
365.32M
90.28%
-6.95M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Cambridge Equities, L.P.
614.63M
69.64%
+117.19M
+23.56%
Apr 21, 2025
Soon-Shiong (Patrick)
35.16M
3.98%
--
--
Apr 21, 2025
The Vanguard Group, Inc.
20.30M
2.3%
+3.01M
+17.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.61M
1.32%
-454.93K
-3.77%
Mar 31, 2025
State Street Global Advisors (US)
7.58M
0.86%
-2.20M
-22.50%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.29M
0.49%
+448.50K
+11.68%
Mar 31, 2025
Woodline Partners LP
3.45M
0.39%
+2.66K
+0.08%
Mar 31, 2025
Simon (Barry J. M.D.)
3.24M
0.37%
--
--
Apr 21, 2025
Citi Investment Research (US)
2.71M
0.31%
+2.33M
+605.88%
Mar 31, 2025
Tang Capital Management, LLC
2.33M
0.26%
-480.86K
-17.09%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Products ETF
1.59%
iShares Genomics Immunology and Healthcare ETF
0.56%
Invesco Nasdaq Biotechnology ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.26%
First Trust Small Cap Growth AlphaDEX Fund
0.19%
SPDR S&P Biotech ETF
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
Goldman Sachs Innovate Equity ETF
0.09%
First Trust Small Cap Core Alphadex Fund
0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.04%
查看更多
Virtus LifeSci Biotech Products ETF
佔比1.59%
iShares Genomics Immunology and Healthcare ETF
佔比0.56%
Invesco Nasdaq Biotechnology ETF
佔比0.26%
ProShares Ultra Nasdaq Biotechnology
佔比0.26%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.19%
SPDR S&P Biotech ETF
佔比0.17%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.1%
Goldman Sachs Innovate Equity ETF
佔比0.09%
First Trust Small Cap Core Alphadex Fund
佔比0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.04%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
